DocMorris (DOCM.SW) Azione Prezzo
DocMorris Prezzo
Il fatturato è cresciuto a un tasso composto del 5,7% annuo negli ultimi 15 anni, raggiungendo 1,12 miliardi CHF. L'utile per azione è cresciuto del 11,2% all'anno negli ultimi 13 anni. Il margine netto di DocMorris si attesta al -12,0%, in aumento rispetto al -13,1% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 8,26 CHF, ovvero il 47,9% sotto il prezzo attuale. Su 13 analisti, 7 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
DocMorris Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
DocMorris Azione e analisi azionaria
Domande frequenti sull'azione DocMorris
The business model of Zur Rose Group AG is focused on providing pharmaceutical and healthcare services. As a leading online pharmacy in Europe, Zur Rose offers a wide range of products and services. The company operates in two segments, namely the Pharmacy and the Services segments. Through its online platform, Zur Rose enables customers to order prescription and over-the-counter drugs, as well as healthcare products, from the comfort of their homes. Additionally, Zur Rose provides services to healthcare professionals, such as logistics and wholesale services. Overall, Zur Rose's business model aims to enhance the accessibility and convenience of pharmaceutical and healthcare products for its customers.
Zur Rose Group AG is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Zur Rose Group AG in the market include established online pharmacy platforms such as Shop Apotheke and DocMorris, as well as traditional brick-and-mortar pharmacies. Zur Rose Group AG competes with these companies by offering a convenient and user-friendly online platform for customers to order prescription and over-the-counter medications. With its strong emphasis on customer service and a wide range of products, Zur Rose Group AG aims to stay competitive in the rapidly growing online pharmacy market.
The Zur Rose Group AG is a renowned Swiss company specializing in healthcare and pharmacy services. Founded in 1993 by Walter Oberhänsli, it started as a local pharmacy in Zurich. Over the years, Zur Rose Group AG expanded its operations and established itself as a prominent e-commerce platform for pharmaceuticals, providing customers with easy access to a wide range of healthcare products. The company has since grown into one of Europe's leading online pharmacies, serving millions of customers across multiple countries. With its commitment to innovation and customer-centric approach, Zur Rose Group AG continues to revolutionize the healthcare industry by combining digital solutions with traditional pharmaceutical services.
Zur Rose Group AG, a leading online pharmacy in Europe, has achieved several significant milestones. The company went public in 2017, making it the first publicly traded online pharmacy in Switzerland. In 2018, Zur Rose Group AG acquired the pharmacy business of medpex, Germany's second-largest online pharmacy. This strategic move strengthened its position in Europe's largest pharmaceutical market. In 2020, the company successfully completed the acquisition of Apotal, another prominent online pharmacy in Germany. These milestones demonstrate Zur Rose Group AG's commitment to expanding its market presence, enhancing customer access to high-quality healthcare products, and solidifying its position as a trusted online pharmacy leader.
Zur Rose Group AG is primarily present in countries and regions including Switzerland, Germany, and Austria.
Zur Rose Group AG is a leading online pharmacy and healthcare provider. With a strong focus on customer satisfaction and quality, the company aims to improve the health and well-being of its customers. Its corporate philosophy revolves around innovation, efficiency, and sustainability. By utilizing advanced technology and digital solutions, Zur Rose Group AG ensures seamless and convenient access to a wide range of pharmaceutical products and healthcare services. The company places great value on trust, reliability, and transparency, aiming to establish long-lasting relationships with its customers. Zur Rose Group AG's commitment to providing accessible and affordable healthcare sets it apart in the industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 9,52 CHF per l’azione DocMorris (mediana: 8,26 CHF), pari a -39,9 % rispetto all’ultimo prezzo. Il consenso si basa su 13 giudizi di analisti.
14 analisti valutano attualmente l’azione DocMorris: 1 raccomandano l’acquisto, 6 la tenuta e 7 la vendita. Per il 2026 gli analisti si aspettano per DocMorris ricavi pari a 1,26 miliardi CHF e un utile per azione di -1,66 CHF.
Convertita al tasso di cambio attuale, l’azione DocMorris quota 17,10 EUR (15,85 CHF).
L’azione DocMorris (DOCM.SW) è quotata su 7 borse, tra cui: London (0RRB.L), SIX (Zürich) (ROSE.SW), Frankfurt (ZRE.F), München (ZRE.MU), Düsseldorf (ZRE.DU).
The Zur Rose Group AG is a leading company in the healthcare sector and offers a wide range of products and services, ranging from pharmaceuticals to care products to medical advice and healthcare services. The company is headquartered in Switzerland and operates in several European countries, including Germany, Austria, France, Spain, and Italy. The core business of the Zur Rose Group AG is the online sale of prescription and over-the-counter medications. Customers can order their medications through the Zur Rose Group AG platform and have them delivered to their homes free of charge. In order to provide this service, the Zur Rose Group AG has built its own mail-order pharmacy that complies with all legal requirements and where all medications are checked by qualified pharmacists. In addition to the mail-order pharmacy, the Zur Rose Group AG also operates a number of local pharmacies, known as "DocMorris." These pharmacies also offer prescription and over-the-counter medications, as well as care products and advice from qualified pharmacists. The Zur Rose Group AG has set itself the goal of becoming the leading pharmacy brand in Europe and is therefore continuously expanding into new markets. Another important business area of the Zur Rose Group AG is healthcare services. Here, the company offers services such as medical advice over the phone, email, or live chat. The Zur Rose Group AG also operates its own health centers, where patients can receive medical advice and treatment, as well as various health checks and preventive examinations. In order to further expand its business, the Zur Rose Group AG has also invested in other areas in recent years. For example, the company has developed the platform "smartpatient," which supports patients in managing their health data and informing themselves about their illnesses and treatment options. In addition, the Zur Rose Group AG has a stake in the company Medpex, an online shop for pharmaceuticals and care products. Overall, the Zur Rose Group AG pursues a broad-based business model based on various pillars. The company benefits from the growing trend towards online commerce and digital healthcare. At the same time, the Zur Rose Group AG also relies on proven concepts such as local pharmacies to ensure comprehensive access to medications and healthcare services. In the future, the Zur Rose Group AG is likely to continue to grow strongly and further expand its position as one of the leading providers in the healthcare sector.
Il attesa fatturato di DocMorris ammonta a 1,26 miliardi CHF. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di DocMorris ammonta a -85,70 Mio. CHF. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di DocMorris è attualmente -9,55. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione DocMorris.
Il rapporto prezzo/fatturato (P/S) di DocMorris è attualmente 0,65. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione DocMorris.
Il Quality Score AlleAktien per DocMorris è 2/10.
L'ISIN di DocMorris è CH0042615283. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di DocMorris è A0Q6J0. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di DocMorris è DOCM.SW. Con questo simbolo di borsa vengono negoziate le azioni DocMorris in borsa.
Azione DocMorris
Gruppo di pari di DocMorris
DocMorris Ticker
DocMorris FIGI
Altre metriche e analisi di DocMorris in Deep Dive.
La nostra analisi azionaria dell'azione DocMorris include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di DocMorris. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: